Last reviewed · How we verify
ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma
This is a single center, open-label, 3+3 dose escalation, phase 1 study to evaluate the efficacy and safety of ET019003-T cells therapy for patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and lymphoma.
Details
| Lead sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
|---|---|
| Phase | PHASE1 |
| Status | UNKNOWN |
| Enrolment | 9 |
| Start date | Wed Jun 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Jul 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Leukemia
- Lymphoma
Interventions
- ET019003-T Cells
Countries
China